This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
SCHAUMBURG, Ill., Nov. 6, 2013 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the launch of Levetiracetam Injection, the generic form of the antiepileptic Keppra®, in a preservative-free glass vial. According to IMS, for the 12 months ending September 2013, the US market for Levetiracetam Injection approximated $47 million. As with all products in Sagent's portfolio, Levetiracetam features Sagent's PreventIV Measures
SM packaging and labeling, designed to help reduce medication errors.
About Levetiracetam Injection
Levetiracetam Injection is indicated in adult patients (≥16 years of age), as adjunctive therapy, when oral administration is temporarily not feasible for treatment of the following: partial onset seizures, myoclonic seizures in those with juvenile myoclonic epilepsy, or primary generalized tonic-clonic seizures in those with idiopathic generalized epilepsy.
The package insert, available at
www.SagentPharma.com , contains the indications, complete side effect profile and prescribing information.
About Sagent Pharmaceuticals, Inc.
Sagent Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectables. Sagent has created a unique global network of resources, comprising rapid development capabilities, sophisticated manufacturing and innovative drug delivery technologies, resulting in an extensive and rapidly expanding pharmaceutical product portfolio that fulfills the evolving needs of patients.